LYEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LYEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Lyell Immunopharma's gross profit for the three months ended in Dec. 2024 was $0.01 Mil. Lyell Immunopharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.06 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Lyell Immunopharma's gross profit for the three months ended in Dec. 2024 was $0.01 Mil. Lyell Immunopharma's Revenue for the three months ended in Dec. 2024 was $0.01 Mil. Therefore, Lyell Immunopharma's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.
Lyell Immunopharma had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
The historical data trend for Lyell Immunopharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Gross Profit | Get a 7-Day Free Trial | 7.76 | 10.65 | 84.68 | 0.13 | 0.06 |
Lyell Immunopharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.01 | - | 0.01 | 0.03 | 0.01 |
For the Biotechnology subindustry, Lyell Immunopharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Lyell Immunopharma's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as
Gross Profit (A: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 0.061 | - | 0 | |
= | 0.06 |
Lyell Immunopharma's Gross Profit for the quarter that ended in Dec. 2024 is calculated as
Gross Profit (Q: Dec. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 0.011 | - | 0 | |
= | 0.01 |
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Lyell Immunopharma's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.01 | / | 0.011 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lyell Immunopharma (NAS:LYEL) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lyell Immunopharma had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Thank you for viewing the detailed overview of Lyell Immunopharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles W. Newton | officer: Chief Financial Officer | 46 FREDRICK AVENUE, ATHERTON CA 94027 |
Lynn Seely | director | 501 2ND STREET, SUITE 211, SAN FRANCISCO CA 94107 |
Richard Klausner | director, officer: Executive Chairman | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Matthew Lang | officer: Chief Business Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Rahsaan Thompson | officer: Chief Legal Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Tina M. Albertson | officer: Chief Medical Officer | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080 |
Gary K. Lee | officer: Chief Scientific Officer | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080 |
Cathy Friedman | director | C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005 |
Arch Venture Fund Ix Overage, L.p. | 10 percent owner | 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
Elizabeth Homans | director, officer: Chief Executive Officer | C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080 |
Stephen J. Hill | officer: Chief Technical Ops. Officer | C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080 |
Otis W Brawley | director | 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518 |
Elizabeth G Nabel | director | BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115 |
William Jl Rieflin | director | NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Arch Venture Partners Ix, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By GuruFocus Research • 02-28-2024
By Marketwired • 10-24-2024
By Marketwired • 12-10-2024
By PRNewswire • 09-11-2023
By Marketwired • 01-09-2025
By Marketwired • 08-31-2023
By Marketwired • 09-11-2023
By Stock market mentor Stock market mentor • 01-03-2023
By GuruFocus News • 11-05-2024
By sperokesalga sperokesalga • 05-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.